Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to a significant drop in stock price following the FDA's clinical hold on its RP-A501 treatment trial after a patient death, which was not disclosed until after the event occurred [2][3][4]. Group 1: Company Background - Rocket Pharmaceuticals, Inc. is involved in developing treatments for rare diseases, specifically focusing on Danon disease with its RP-A501 treatment [2]. Group 2: Incident Details - On May 27, 2025, Rocket disclosed that the FDA had placed a clinical hold on its Phase 2 pivotal trial of RP-A501 after a patient death occurred following an undisclosed protocol amendment [2][4]. - The stock price of Rocket fell by $3.94, or 62.8%, closing at $2.33 per share on the same day [3]. Group 3: Lawsuit Allegations - The class action lawsuit alleges that Rocket made materially false and misleading statements and failed to disclose adverse facts about its business and operations during the class period [4]. - Specific allegations include that Rocket was aware of the risks of serious adverse events, including participant deaths, and did not inform shareholders about a critical protocol amendment involving a new immunomodulatory agent [4].

Core Insights - Rocket Pharmaceuticals (RCKT) has received FDA clearance for its investigational new drug application to initiate clinical studies for its gene therapy candidate RP-A701, aimed at treating BAG3-associated dilated cardiomyopathy [1][6] - The planned phase I study will assess the safety, biological activity, and preliminary efficacy of RP-A701 in adults with BAG3-DCM, a rare genetic heart condition [2][6] Company Pipeline - RCKT is also developing another gene therapy candidate, RP-A601, which is in early-stage development for arrhythmogenic cardiomyopathy [3] - Recent setbacks in the company's pipeline, including a voluntary pause in the phase II study of RP-A501 due to a patient death, have raised concerns [4][7] - The FDA has issued a complete response letter regarding the biologics license application for Kresladi, requesting additional information [8] Stock Performance - Year to date, RCKT's shares have declined by 80.5%, contrasting with a 3.6% decline in the industry [3] - The company currently holds a Zacks Rank of 3 (Hold), while other biotech stocks like Exelixis, Spero Therapeutics, and Puma Biotechnology have better rankings [9]

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in a significant drop in stock price after the FDA placed a clinical hold on the study following a Serious Adverse Event [2][3]. Group 1: Allegations and Events - The lawsuit claims that Rocket Pharmaceuticals provided overly positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) and participant deaths [2]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 to $2.33 per share, a decline of approximately 37% in one trading day [2]. Group 2: Shareholder Actions - Shareholders who purchased RCKT shares during the class period from February 27, 2025, to May 26, 2025, are encouraged to register for the class action lawsuit, with a deadline of August 11, 2025, to seek lead plaintiff status [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle, with no cost or obligation to participate [3]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, seeking recovery for losses incurred due to misleading statements by companies [4].

Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. concerning allegations of securities fraud and unlawful business practices related to the company's investigational gene therapy for Danon disease [1][2]. Group 1: Lawsuit Details - The lawsuit involves claims that Rocket and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Rocket securities during the Class Period have until August 11, 2025, to request to be appointed as Lead Plaintiff [2]. Group 2: Incident Background - On May 27, 2025, Rocket announced an unexpected Serious Adverse Event (SAE) involving a patient in the Phase 2 trial of RP-A501, which led to a clinical hold by the FDA [4]. - Following the announcement, Rocket's stock price dropped by $3.94 per share, or 62.84%, closing at $2.33 per share [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals, Inc. securities between February 27, 2025, and May 26, 2025, of the upcoming lead plaintiff deadline on August 11, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 11, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that Rocket Pharmaceuticals provided misleading statements regarding the safety and clinical trial protocol of RP-A501, concealing material adverse facts, including the risk of Serious Adverse Events (SAEs) [5]. - It is claimed that Rocket Pharmaceuticals amended the trial protocol without informing shareholders, leading to artificially inflated stock prices [5].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 27, 2025, and May 26, 2025 [1]. - Defendants allegedly made positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) [2]. - Following the announcement of a clinical hold by the FDA due to a SAE, Rocket's stock price plummeted from $6.27 on May 23, 2025, to $2.33 on May 27, 2025, marking a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until August 11, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

NEW YORK, June 27, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Rocket and certain of its o ...

Core Viewpoint - A securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly misleading investors regarding the safety and clinical trial protocol of its RP-A501 treatment, particularly concerning Serious Adverse Events (SAEs) that occurred during the trial [1][2][4]. Group 1: Allegations and Misrepresentation - The lawsuit claims that Rocket provided overly positive statements while concealing material adverse facts about the safety of RP-A501 and the risks associated with the clinical trial, including the death of participants [2][3]. - Rocket amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to inflated stock prices based on misleading information [3][4]. Group 2: Impact of the Clinical Hold - On May 27, 2025, Rocket announced that the FDA had placed a clinical hold on the RP-A501 Phase 2 pivotal study after a patient experienced a Serious Adverse Event resulting in death, which was not disclosed to investors prior to the amendment [4]. - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% [5]. Group 3: Legal Representation - Wolf Haldenstein Adler Freeman & Herz LLP is representing the investors in this case, emphasizing their long-standing expertise in securities litigation and commitment to protecting investor rights [5][6].

NEW YORK, June 27, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/rocket-pharmaceuticals-i ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to significant losses suffered by investors following misleading statements regarding the safety of its clinical trial for RP-A501 [2][4]. Group 1: Company Overview - Rocket Pharmaceuticals, Inc. is a publicly traded company on NASDAQ under the ticker RCKT [2]. - The company has faced scrutiny for its handling of clinical trial protocols and communication with investors [4]. Group 2: Legal Actions and Investigations - A federal securities class action has been filed against Rocket Pharmaceuticals, with a deadline of August 11, 2025, for investors to seek the role of lead plaintiff [2][7]. - Faruqi & Faruqi encourages investors who suffered losses exceeding $50,000 between February 27, 2025, and May 26, 2025, to discuss their legal options [1]. Group 3: Clinical Trial Issues - The complaint alleges that Rocket Pharmaceuticals provided overly positive statements while concealing material adverse facts about the safety of RP-A501 and the clinical trial protocol [4]. - On May 27, 2025, the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after a patient suffered a Serious Adverse Event, including death, which was not disclosed to investors prior to the incident [5]. Group 4: Stock Price Impact - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in just one trading day [6].